| RESEARCH ARTICLE |
|
| Year : 2013 | Volume
: 45
| Issue : 3 | Page : 217-222 |
Effect of Agaricus sylvaticus supplementation on nutritional status and adverse events of chemotherapy of breast cancer: A randomized, placebo-controlled, double-blind clinical trial
Fabiana Valadares1, Maria Rita Carvalho Garbi Novaes2, Roberto Cañete3
1 Departamento de Nutrição Clínica- University of Brasilia-DF, Brazil
2 Departamento de Farmacologia- School of Medicine Institute of Health Science-ESCS, University of Brasilia, Brazil
3 Department of Parasitology- Centre for Hygiene, Epidemiology and Microbiology-Matanzas and Cuban Institute of Gastroenterology-Havana City, Cuba
Correspondence Address:
Roberto Cañete
Department of Parasitology- Centre for Hygiene, Epidemiology and Microbiology-Matanzas and Cuban Institute of Gastroenterology-Havana City
Cuba
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0253-7613.111894
Background: Breast cancer (BC) represents the highest incidence of malignancy in women throughout the world. Medicinal fungi can stimulate the body, reduce side-effects associated with chemotherapy and improve the quality of life in patients with cancer.
Aim: To evaluate the effects of dietary supplementation of Agaricus sylvaticus on clinical and nutritional parameters in BC patients undergoing chemotherapy.
Materials and Methods: A randomized, placebo-controlled, double-blind, clinical trial was carried out at the Oncology Clinic, Hospital of the Federal District-Brazil from September 2007 to July 2009. Forty six patients with BC, Stage II and III, were randomly assigned to receive either nutritional supplement with A. sylvaticus (2.1 g/day) or placebo. Patients were evaluated during treatment period.
Results: Patient supplemented with A. sylvaticus improved in clinical parameters and gastrointestinal functions. Poor appetite decreased by 20% with no changes in bowel functions (92.8%), nausea and vomiting (80%).
Conclusion: Dietary supplementation with A. sylvaticus improved nutritional status and reduced abnormal bowel functions, nausea, vomiting, and anorexia in patients with BC receiving chemotherapy.
[FULL TEXT] [PDF]*
|
